| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.592 | 0.051 | 0.592 | Apoptosis agonist | 0.535 0.064 DBMET03353 | ||
| 0.553 | 0.019 | 0.553 | 5 Hydroxytryptamine release inhibitor | 0.456 0.049 DBMET03353 | ||
| 0.531 | 0.041 | 0.621 | Analgesic | 0.621 0.023 DBMET03353 | DBMET03353 | |
| 0.507 | 0.026 | 0.507 | Vasodilator, peripheral | 0.411 0.052 DBMET03353 | ||
| 0.499 | 0.06 | 0.499 | Caspase 9 stimulant | 0.435 0.091 DBMET03353 | ||
| 0.444 | 0.021 | 0.503 | Hypoxia-inducible factor 1 alpha inhibitor | 0.503 0.014 DBMET03353 | DBMET03353 | |
| 0.443 | 0.044 | 0.494 | GABA C receptor rho-3 antagonist | 0.494 0.027 DBMET03353 | DBMET03353 | |
| 0.423 | 0.045 | 0.423 | Cholesterol antagonist | 0.34 0.069 DBMET03353 | ||
| 0.403 | 0.028 | 0.403 | DNA damaging | 0.378 0.033 DBMET03353 | ||
| 0.42 | 0.065 | 0.42 | Histamine release inhibitor | 0.399 0.076 DBMET03353 | ||
| 0.358 | 0.031 | 0.358 | Transcription factor STAT inhibitor | 0.353 0.033 DBMET03353 | ||
| 0.365 | 0.041 | 0.365 | Calcium channel activator | 0.337 0.059 DBMET03353 | ||
| 0.309 | 0.009 | 0.309 | Nitric-oxide synthase stimulant | 0.285 0.016 DBMET03353 | ||
| 0.32 | 0.021 | 0.32 | Gastrin inhibitor | 0.255 0.073 DBMET03353 | ||
| 0.344 | 0.058 | 0.344 | Vasodilator, coronary | 0.277 0.108 DBMET03353 | ||
| 0.33 | 0.068 | 0.471 | Streptokinase A inhibitor | 0.471 0.033 DBMET03353 | DBMET03353 | |
| 0.332 | 0.085 | 0.372 | Thioredoxin glutathione reductase inhibitor | 0.372 0.068 DBMET03353 | DBMET03353 | |
| 0.252 | 0.016 | 0.299 | DNA intercalator | 0.299 0.012 DBMET03353 | DBMET03353 | |
| 0.266 | 0.03 | 0.266 | Neurotrophic factor enhancer | 0.265 0.031 DBMET03353 | ||
| 0.286 | 0.057 | 0.286 | Platelet antagonist | 0.17 0.126 DBMET03353 | ||
| 0.276 | 0.057 | 0.276 | Vasodilator | 0.195 0.108 DBMET03353 | ||
| 0.22 | 0.008 | 0.281 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.281 0.005 DBMET03353 | DBMET03353 | |
| 0.273 | 0.062 | 0.448 | Superoxide dismutase inhibitor | 0.448 0.019 DBMET03353 | DBMET03353 | |
| 0.221 | 0.01 | 0.422 | Porphobilinogen synthase inhibitor | 0.422 0.004 DBMET03353 | DBMET03353 | |
| 0.295 | 0.091 | 0.295 | Antithrombotic | 0.208 0.168 DBMET03353 | ||
| 0.341 | 0.14 | 0.495 | Alpha-glucosidase inhibitor | 0.495 0.082 DBMET03353 | DBMET03353 | |
| 0.24 | 0.047 | 0.24 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.202 0.07 DBMET03353 | ||
| 0.213 | 0.022 | 0.213 | Arachidonic acid antagonist | 0.191 0.042 DBMET03353 | ||
| 0.266 | 0.082 | 0.31 | 5 Hydroxytryptamine release stimulant | 0.31 0.067 DBMET03353 | DBMET03353 | |
| 0.191 | 0.009 | 0.191 | Keratolytic | 0.166 0.012 DBMET03353 | ||
| 0.231 | 0.052 | 0.231 | Non-steroidal antiinflammatory agent | |||
| 0.212 | 0.036 | 0.212 | Phospholipase A2 inhibitor | 0.177 0.055 DBMET03353 | ||
| 0.184 | 0.009 | 0.24 | Transcription factor STAT6 inhibitor | 0.24 0.005 DBMET03353 | DBMET03353 | |
| 0.193 | 0.021 | 0.193 | Cyclooxygenase 3 inhibitor | 0.12 0.077 DBMET03353 | ||
| 0.303 | 0.133 | 0.319 | Antibacterial | 0.319 0.121 DBMET03353 | DBMET03353 | |
| 0.336 | 0.167 | 0.375 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.375 0.124 DBMET03353 | DBMET03353 | |
| 0.18 | 0.011 | 0.244 | HIV-1 integrase (3'-Processing) inhibitor | 0.244 0.007 DBMET03353 | DBMET03353 | |
| 0.173 | 0.008 | 0.26 | Interleukin 5 antagonist | 0.26 0.004 DBMET03353 | DBMET03353 | |
| 0.214 | 0.056 | 0.56 | Peroxidase inhibitor | 0.56 0.005 DBMET03353 | DBMET03353 | |
| 0.169 | 0.011 | 0.202 | HIV-1 integrase (Strand Transfer) inhibitor | 0.202 0.009 DBMET03353 | DBMET03353 | |
| 0.173 | 0.027 | 0.173 | Beta amyloid protein antagonist | 0.162 0.033 DBMET03353 | ||
| 0.183 | 0.037 | 0.212 | Monophenol monooxygenase inhibitor | 0.212 0.03 DBMET03353 | DBMET03353 | |
| 0.147 | 0.007 | 0.147 | Elastase 1 inhibitor | |||
| 0.138 | 0.004 | 0.185 | Complement C3a chemotactic receptor antagonist | 0.185 0.003 DBMET03353 | DBMET03353 | |
| 0.183 | 0.05 | 0.237 | Acetylcholine M1 receptor antagonist | 0.237 0.029 DBMET03353 | DBMET03353 | |
| 0.237 | 0.109 | 0.237 | Lipoxygenase inhibitor | 0.224 0.119 DBMET03353 | ||
| 0.199 | 0.075 | 0.199 | Anesthetic general | 0.187 0.082 DBMET03353 | ||
| 0.155 | 0.032 | 0.155 | Ca2+-transporting ATPase inhibitor | 0.151 0.04 DBMET03353 | ||
| 0.228 | 0.106 | 0.287 | 5 Hydroxytryptamine uptake stimulant | 0.287 0.052 DBMET03353 | DBMET03353 | |
| 0.169 | 0.048 | 0.177 | CF transmembrane conductance regulator agonist | 0.177 0.039 DBMET03353 | DBMET03353 | |
| 0.197 | 0.083 | 0.197 | Platelet aggregation inhibitor | |||
| 0.204 | 0.094 | 0.233 | RNA-directed DNA polymerase inhibitor | 0.233 0.061 DBMET03353 | DBMET03353 | |
| 0.124 | 0.015 | 0.124 | Calcium channel L-type blocker | |||
| 0.136 | 0.028 | 0.136 | Acetylcholine release stimulant | 0.133 0.031 DBMET03353 | ||
| 0.242 | 0.134 | 0.242 | Transcription factor NF kappa B inhibitor | 0.206 0.163 DBMET03353 | ||
| 0.124 | 0.016 | 0.124 | Acetylcholine M4 receptor antagonist | 0.106 0.024 DBMET03353 | ||
| 0.164 | 0.057 | 0.18 | GABA C receptor rho-2 antagonist | 0.18 0.042 DBMET03353 | DBMET03353 | |
| 0.14 | 0.033 | 0.14 | Mediator release inhibitor | 0.114 0.054 DBMET03353 | ||
| 0.166 | 0.06 | 0.166 | Interferon gamma antagonist | 0.162 0.064 DBMET03353 | ||
| 0.179 | 0.072 | 0.179 | Lipocortins synthesis antagonist | |||
| 0.137 | 0.033 | 0.137 | Gastric antisecretory | 0.121 0.042 DBMET03353 | ||
| 0.2 | 0.097 | 0.266 | Free radical scavenger | 0.266 0.062 DBMET03353 | DBMET03353 | |
| 0.14 | 0.039 | 0.14 | TRPA1 agonist | 0.112 0.068 DBMET03353 | ||
| 0.211 | 0.11 | 0.211 | Interleukin agonist | |||
| 0.155 | 0.055 | 0.165 | Adenylate cyclase stimulant | 0.165 0.042 DBMET03353 | DBMET03353 | |
| 0.202 | 0.101 | 0.202 | Aryl hydrocarbon receptor agonist | 0.17 0.121 DBMET03353 | ||
| 0.106 | 0.007 | 0.142 | Aconitate hydratase inhibitor | 0.142 0.004 DBMET03353 | DBMET03353 | |
| 0.109 | 0.012 | 0.196 | Alpha 2 adrenoreceptor agonist | 0.196 0.004 DBMET03353 | DBMET03353 | |
| 0.11 | 0.015 | 0.11 | Estrogen-related receptor beta agonist | 0.101 0.023 DBMET03353 | ||
| 0.14 | 0.05 | 0.14 | Cholesterol synthesis inhibitor | 0.131 0.056 DBMET03353 | ||
| 0.12 | 0.031 | 0.12 | Thioredoxin inhibitor | |||
| 0.108 | 0.02 | 0.117 | Aromatase inhibitor | 0.117 0.018 DBMET03353 | DBMET03353 | |
| 0.202 | 0.117 | 0.271 | Neuropeptide Y2 antagonist | 0.271 0.038 DBMET03353 | DBMET03353 | |
| 0.097 | 0.012 | 0.125 | Dopamine transporter inhibitor | 0.125 0.008 DBMET03353 | DBMET03353 | |
| 0.101 | 0.018 | 0.156 | Adrenaline uptake inhibitor | 0.156 0.009 DBMET03353 | DBMET03353 | |
| 0.108 | 0.026 | 0.11 | Granulocyte macrophage colony stimulating factor agonist | 0.11 0.023 DBMET03353 | DBMET03353 | |
| 0.1 | 0.018 | 0.21 | Alcohol oxidase inhibitor | 0.21 0.006 DBMET03353 | DBMET03353 | |
| 0.138 | 0.058 | 0.138 | Antibacterial (Helicobacter pylori) | 0.106 0.105 DBMET03353 | ||
| 0.114 | 0.039 | 0.139 | Alcohol dehydrogenase inhibitor | 0.139 0.024 DBMET03353 | DBMET03353 | |
| 0.101 | 0.026 | 0.101 | Leukotriene synthesis inhibitor | 0.066 0.047 DBMET03353 | ||
| 0.096 | 0.027 | 0.137 | HIV-1 integrase inhibitor | 0.137 0.011 DBMET03353 | DBMET03353 | |
| 0.106 | 0.036 | 0.193 | Topoisomerase II alpha inhibitor | 0.193 0.016 DBMET03353 | DBMET03353 | |
| 0.125 | 0.055 | 0.125 | Microtubule formation inhibitor | |||
| 0.171 | 0.103 | 0.235 | Interleukin antagonist | 0.235 0.067 DBMET03353 | DBMET03353 | |
| 0.173 | 0.104 | 0.173 | Insulin sensitizer | |||
| 0.216 | 0.148 | 0.216 | Caspase 3 stimulant | |||
| 0.201 | 0.134 | 0.289 | Tyrosine 3 hydroxylase inhibitor | 0.289 0.039 DBMET03353 | DBMET03353 | |
| 0.122 | 0.056 | 0.272 | Cystathionine beta-synthase inhibitor | 0.272 0.012 DBMET03353 | DBMET03353 | |
| 0.085 | 0.02 | 0.085 | Exportin-1 inhibitor | |||
| 0.136 | 0.071 | 0.156 | Bone formation stimulant | 0.156 0.054 DBMET03353 | DBMET03353 | |
| 0.218 | 0.155 | 0.218 | Ca(v)3.3 blocker | 0.211 0.169 DBMET03353 | ||
| 0.134 | 0.073 | 0.134 | Calcium channel blocker | |||
| 0.072 | 0.012 | 0.072 | Pregnane X receptor antagonist | 0.062 0.027 DBMET03353 | ||
| 0.127 | 0.067 | 0.143 | Cholinergic antagonist | 0.143 0.057 DBMET03353 | DBMET03353 | |
| 0.091 | 0.032 | 0.207 | Alpha adrenoreceptor agonist | 0.207 0.008 DBMET03353 | DBMET03353 | |
| 0.217 | 0.159 | 0.217 | Apoptosis antagonist | |||
| 0.116 | 0.058 | 0.139 | Chelator | 0.139 0.04 DBMET03353 | DBMET03353 | |
| 0.089 | 0.031 | 0.089 | Amidase inhibitor | 0.069 0.05 DBMET03353 | ||
| 0.106 | 0.049 | 0.11 | Prolactin inhibitor | 0.11 0.046 DBMET03353 | DBMET03353 | |
| 0.123 | 0.068 | 0.14 | Acetylcholine antagonist | 0.14 0.056 DBMET03353 | DBMET03353 | |
| 0.059 | 0.005 | 0.059 | Vanilloid 3 antagonist | 0.052 0.007 DBMET03353 | ||
| 0.217 | 0.165 | 0.258 | Sodium/bile acid cotransporter inhibitor | 0.258 0.12 DBMET03353 | DBMET03353 | |
| 0.101 | 0.049 | 0.101 | Toll-Like receptor 3 antagonist | 0.098 0.053 DBMET03353 | ||
| 0.093 | 0.042 | 0.2 | Adrenaline agonist | 0.2 0.007 DBMET03353 | DBMET03353 | |
| 0.083 | 0.032 | 0.087 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.087 0.026 DBMET03353 | DBMET03353 | |
| 0.079 | 0.029 | 0.093 | Glutamate (mGluR7) antagonist | 0.093 0.015 DBMET03353 | DBMET03353 | |
| 0.069 | 0.018 | 0.069 | Acetyl-CoA transferase 2 inhibitor | |||
| 0.054 | 0.004 | 0.054 | Elastase 3A inhibitor | |||
| 0.054 | 0.004 | 0.054 | Elastase 2B inhibitor | |||
| 0.054 | 0.004 | 0.054 | Elastase 3B inhibitor | |||
| 0.063 | 0.013 | 0.082 | Dopamine beta hydroxylase inhibitor | 0.082 0.005 DBMET03353 | DBMET03353 | |
| 0.154 | 0.105 | 0.181 | Succinate dehydrogenase inhibitor | 0.181 0.067 DBMET03353 | DBMET03353 | |
| 0.152 | 0.103 | 0.152 | Platelet adhesion inhibitor | |||
| 0.061 | 0.012 | 0.061 | Benzodiazepine antagonist | |||
| 0.134 | 0.088 | 0.141 | Pregnane X receptor agonist | 0.141 0.071 DBMET03353 | DBMET03353 | |
| 0.156 | 0.111 | 0.156 | Psychostimulant | |||
| 0.102 | 0.058 | 0.117 | UDP-glucose 4-epimerase inhibitor | 0.117 0.045 DBMET03353 | DBMET03353 | |
| 0.14 | 0.097 | 0.144 | Melanin inhibitor | 0.144 0.09 DBMET03353 | DBMET03353 | |
| 0.115 | 0.073 | 0.142 | Acetylcholine muscarinic antagonist | 0.142 0.049 DBMET03353 | DBMET03353 | |
| 0.074 | 0.033 | 0.089 | Acetylcholine M2 receptor antagonist | 0.089 0.025 DBMET03353 | DBMET03353 | |
| 0.146 | 0.106 | 0.146 | Tumour necrosis factor antagonist | |||
| 0.065 | 0.026 | 0.065 | Ryanodine receptor antagonist | 0.06 0.036 DBMET03353 | ||
| 0.11 | 0.07 | 0.11 | Calcium channel (voltage-sensitive) blocker | |||
| 0.093 | 0.053 | 0.093 | Calcium antagonist | |||
| 0.107 | 0.068 | 0.107 | Mucolytic | |||
| 0.118 | 0.08 | 0.118 | Toll-Like receptor 2 antagonist | 0.109 0.091 DBMET03353 | ||
| 0.11 | 0.072 | 0.11 | Photosensitizer | |||
| 0.195 | 0.157 | 0.308 | 12-Lipoxygenase inhibitor | 0.308 0.075 DBMET03353 | DBMET03353 | |
| 0.065 | 0.029 | 0.065 | Prostaglandin antagonist | 0.065 0.029 DBMET03353 | ||
| 0.045 | 0.009 | 0.045 | Methionyl aminopeptidase 1 inhibitor | 0.035 0.018 DBMET03353 | ||
| 0.13 | 0.094 | 0.15 | Diuretic | 0.15 0.078 DBMET03353 | DBMET03353 | |
| 0.049 | 0.013 | 0.052 | Prostacyclin antagonist | 0.052 0.012 DBMET03353 | DBMET03353 | |
| 0.042 | 0.006 | 0.042 | Elastase 2A inhibitor | |||
| 0.042 | 0.006 | 0.042 | Elastase 2 inhibitor | |||
| 0.051 | 0.017 | 0.061 | Histamine H1 receptor agonist | 0.061 0.008 DBMET03353 | DBMET03353 | |
| 0.17 | 0.136 | 0.179 | 5 Hydroxytryptamine 3E antagonist | 0.179 0.109 DBMET03353 | DBMET03353 | |
| 0.173 | 0.139 | 0.226 | Antioxidant | 0.226 0.098 DBMET03353 | DBMET03353 | |
| 0.057 | 0.027 | 0.057 | Glucose-6-phosphate translocase inhibitor | |||
| 0.151 | 0.121 | 0.151 | Antimitotic | |||
| 0.1 | 0.07 | 0.155 | Beta glucuronidase inhibitor | 0.155 0.022 DBMET03353 | DBMET03353 | |
| 0.143 | 0.114 | 0.143 | 3C-like protease (Human coronavirus) inhibitor | 0.134 0.132 DBMET03353 | ||
| 0.079 | 0.051 | 0.079 | Nicotinic alpha4beta2 receptor antagonist | 0.079 0.051 DBMET03353 | ||
| 0.096 | 0.068 | 0.098 | Anabolic | 0.098 0.065 DBMET03353 | DBMET03353 | |
| 0.079 | 0.053 | 0.102 | Macrophage migration inhibitory factor inhibitor | 0.102 0.033 DBMET03353 | DBMET03353 | |
| 0.08 | 0.054 | 0.08 | Acetylcholine nicotinic antagonist | |||
| 0.061 | 0.036 | 0.071 | Botulinum neurotoxin type A inhibitor | 0.071 0.024 DBMET03353 | DBMET03353 | |
| 0.193 | 0.168 | 0.274 | Nootropic | 0.274 0.089 DBMET03353 | DBMET03353 | |
| 0.056 | 0.034 | 0.061 | Thromboxane synthase inhibitor | 0.061 0.026 DBMET03353 | DBMET03353 | |
| 0.134 | 0.112 | 0.134 | Nitric oxide antagonist | |||
| 0.038 | 0.016 | 0.038 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.049 | 0.028 | 0.049 | Oleamide hydrolase inhibitor | |||
| 0.059 | 0.039 | 0.063 | Sphingosine 1-phosphate receptor 3 antagonist | 0.063 0.034 DBMET03353 | DBMET03353 | |
| 0.083 | 0.064 | 0.083 | Ornithine decarboxylase inhibitor | 0.078 0.07 DBMET03353 | ||
| 0.024 | 0.006 | 0.063 | Alpha 2b adrenoreceptor agonist | 0.063 0.003 DBMET03353 | DBMET03353 | |
| 0.08 | 0.063 | 0.08 | GABA A receptor agonist | |||
| 0.036 | 0.02 | 0.036 | HMG CoA reductase inhibitor | 0.034 0.025 DBMET03353 | ||
| 0.131 | 0.116 | 0.164 | Heat shock protein 70 antagonist | 0.164 0.023 DBMET03353 | DBMET03353 | |
| 0.036 | 0.021 | 0.036 | Free fatty acid receptor 1 antagonist | |||
| 0.155 | 0.141 | 0.223 | Antiamyloidogenic | 0.223 0.085 DBMET03353 | DBMET03353 | |
| 0.027 | 0.013 | 0.029 | Prostaglandin D2 antagonist | 0.029 0.012 DBMET03353 | DBMET03353 | |
| 0.085 | 0.072 | 0.152 | HIV-1 integrase (Overall Integration) inhibitor | 0.152 0.024 DBMET03353 | DBMET03353 | |
| 0.104 | 0.091 | 0.133 | Aldehyde dehydrogenase inhibitor | 0.133 0.059 DBMET03353 | DBMET03353 | |
| 0.054 | 0.042 | 0.083 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.083 0.019 DBMET03353 | DBMET03353 | |
| 0.064 | 0.052 | 0.182 | Phenylalanine 4-hydroxylase inhibitor | 0.182 0.008 DBMET03353 | DBMET03353 | |
| 0.086 | 0.077 | 0.213 | Creatine kinase inhibitor | 0.213 0.009 DBMET03353 | DBMET03353 | |
| 0.056 | 0.047 | 0.099 | Acetylcholine M3 receptor antagonist | 0.099 0.018 DBMET03353 | DBMET03353 | |
| 0.137 | 0.128 | 0.247 | Pyruvate kinase inhibitor | 0.247 0.062 DBMET03353 | DBMET03353 | |
| 0.021 | 0.013 | 0.032 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | 0.032 0.009 DBMET03353 | DBMET03353 | |
| 0.086 | 0.078 | 0.089 | Interleukin 1 beta converting enzyme inhibitor | 0.089 0.074 DBMET03353 | DBMET03353 | |
| 0.103 | 0.097 | 0.132 | Alpha-N-acetylglucosaminidase inhibitor | 0.132 0.067 DBMET03353 | DBMET03353 | |
| 0.081 | 0.074 | 0.086 | Triose-phosphate isomerase inhibitor | 0.086 0.066 DBMET03353 | DBMET03353 | |
| 0.088 | 0.082 | 0.166 | GABA C receptor agonist | 0.166 0.028 DBMET03353 | DBMET03353 | |
| 0.042 | 0.038 | 0.042 | Microtubule stabilization | |||
| 0.095 | 0.091 | 0.147 | Topoisomerase II inhibitor | 0.147 0.051 DBMET03353 | DBMET03353 | |
| 0.036 | 0.034 | 0.056 | Dopamine D5 agonist | 0.056 0.014 DBMET03353 | DBMET03353 | |
| 0.082 | 0.079 | 0.089 | 5-Lipoxygenase inhibitor | 0.089 0.072 DBMET03353 | DBMET03353 | |
| 0.108 | 0.107 | 0.108 | Protein kinase stimulant | |||
| 0.05 | 0.049 | 0.065 | Dopamine uptake inhibitor | 0.065 0.034 DBMET03353 | DBMET03353 | |
| 0.12 | 0.12 | 0.131 | CC chemokine 6 receptor antagonist | 0.131 0.066 DBMET03353 | DBMET03353 | |
| 0.016 | 0.017 | 0.029 | Alpha 2c adrenoreceptor agonist | 0.029 0.005 DBMET03353 | DBMET03353 | |
| 0.136 | 0.139 | 0.2 | Phospholipase C inhibitor | 0.2 0.044 DBMET03353 | DBMET03353 | |
| 0.058 | 0.063 | 0.077 | Transcription factor RelA inhibitor | 0.077 0.02 DBMET03353 | DBMET03353 | |
| 0.084 | 0.09 | 0.105 | GABA C receptor rho-1 antagonist | 0.105 0.056 DBMET03353 | DBMET03353 | |
| 0.028 | 0.036 | 0.037 | Purinergic P2Y2 antagonist | 0.037 0.019 DBMET03353 | DBMET03353 | |
| 0.063 | 0.071 | 0.103 | CYP2A6 inhibitor | 0.103 0.034 DBMET03353 | DBMET03353 | |
| 0.084 | 0.093 | 0.095 | Phosphodiesterase 6D inhibitor | 0.095 0.062 DBMET03353 | DBMET03353 | |
| 0.054 | 0.063 | 0.064 | Neuronal nicotinic receptor antagonist | 0.064 0.051 DBMET03353 | DBMET03353 | |
| 0.06 | 0.07 | 0.101 | Glutamate decarboxylase inhibitor | 0.101 0.029 DBMET03353 | DBMET03353 | |
| 0.059 | 0.07 | 0.084 | Aminopeptidase I inhibitor | 0.084 0.039 DBMET03353 | DBMET03353 | |
| 0.045 | 0.056 | 0.05 | Leukotriene B4 antagonist | 0.05 0.045 DBMET03353 | DBMET03353 | |
| 0.049 | 0.061 | 0.078 | Acetylcholine M5 receptor antagonist | 0.078 0.025 DBMET03353 | DBMET03353 | |
| 0.089 | 0.102 | 0.154 | DOPA decarboxylase inhibitor | 0.154 0.019 DBMET03353 | DBMET03353 | |
| 0.028 | 0.043 | 0.042 | Glutamate (mGluR4) agonist | 0.042 0.014 DBMET03353 | DBMET03353 | |
| 0.044 | 0.06 | 0.056 | Nicotinic alpha3beta2 receptor antagonist | 0.056 0.032 DBMET03353 | DBMET03353 | |
| 0.033 | 0.049 | 0.038 | Histamine H2 receptor agonist | 0.038 0.037 DBMET03353 | DBMET03353 | |
| 0.04 | 0.057 | 0.044 | Topoisomerase II beta inhibitor | 0.044 0.043 DBMET03353 | DBMET03353 | |
| 0.031 | 0.052 | 0.053 | Histone deacetylase 9 inhibitor | 0.053 0.014 DBMET03353 | DBMET03353 | |
| 0.032 | 0.055 | 0.061 | Glutamate (mGluR group III) agonist | 0.061 0.018 DBMET03353 | DBMET03353 | |
| 0.025 | 0.049 | 0.052 | Histone deacetylase 7 inhibitor | 0.052 0.018 DBMET03353 | DBMET03353 | |
| 0.015 | 0.039 | 0.021 | Dopamine D1 agonist | 0.021 0.02 DBMET03353 | DBMET03353 | |
| 0.096 | 0.12 | 0.126 | NADPH oxidase inhibitor | 0.126 0.075 DBMET03353 | DBMET03353 | |
| 0.015 | 0.042 | 0.024 | CYP24 inhibitor | 0.024 0.014 DBMET03353 | DBMET03353 | |
| 0.029 | 0.057 | 0.037 | Glutamate (mGluR8) agonist | 0.037 0.028 DBMET03353 | DBMET03353 | |
| 0.062 | 0.094 | 0.125 | Histamine N-methyltransferase inhibitor | 0.125 0.026 DBMET03353 | DBMET03353 | |
| 0.072 | 0.104 | 0.09 | Hematopoietic | 0.09 0.049 DBMET03353 | DBMET03353 | |
| 0.078 | 0.111 | 0.093 | Alpha 2d adrenoreceptor antagonist | 0.093 0.062 DBMET03353 | DBMET03353 | |
| 0.176 | 0.213 | 0.211 | Calpain 2 inhibitor | 0.211 0.178 DBMET03353 | DBMET03353 | |
| 0.079 | 0.118 | 0.119 | GABA C receptor antagonist | 0.119 0.054 DBMET03353 | DBMET03353 | |
| 0.019 | 0.058 | 0.033 | Nicotinic acid receptor agonist | 0.033 0.029 DBMET03353 | DBMET03353 | |
| 0.051 | 0.089 | 0.087 | Histone deacetylase stimulant | 0.087 0.037 DBMET03353 | DBMET03353 | |
| 0.051 | 0.089 | 0.087 | Histone deacetylase SIRT1 stimulant | 0.087 0.037 DBMET03353 | DBMET03353 | |
| 0.079 | 0.121 | 0.092 | Adenylate kinase inhibitor | 0.092 0.082 DBMET03353 | DBMET03353 | |
| 0.073 | 0.115 | 0.088 | Xanthine oxidase inhibitor | 0.088 0.075 DBMET03353 | DBMET03353 | |
| 0.053 | 0.095 | 0.071 | Glutamate dehydrogenase inhibitor | 0.071 0.055 DBMET03353 | DBMET03353 | |
| 0.063 | 0.106 | 0.105 | Aminopeptidase B inhibitor | 0.105 0.062 DBMET03353 | DBMET03353 | |
| 0.041 | 0.085 | 0.075 | Phosphofructokinase-1 inhibitor | 0.075 0.044 DBMET03353 | DBMET03353 | |
| 0.031 | 0.075 | 0.05 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.05 0.015 DBMET03353 | DBMET03353 | |
| 0.065 | 0.109 | 0.141 | Urease inhibitor | 0.141 0.028 DBMET03353 | DBMET03353 | |
| 0.027 | 0.071 | 0.052 | Ribonucleoside-diphosphate reductase inhibitor | 0.052 0.039 DBMET03353 | DBMET03353 | |
| 0.105 | 0.151 | 0.207 | Amyloid beta aggregation inhibitor | 0.207 0.074 DBMET03353 | DBMET03353 | |
| 0.143 | 0.19 | 0.166 | Calpain inhibitor | 0.166 0.154 DBMET03353 | DBMET03353 | |
| 0.025 | 0.073 | 0.042 | HIV-1 protease inhibitor | 0.042 0.031 DBMET03353 | DBMET03353 | |
| 0.025 | 0.074 | 0.052 | Ribonucleotide reductase inhibitor | 0.052 0.041 DBMET03353 | DBMET03353 | |
| 0.015 | 0.065 | 0.034 | Nicotinic alpha3beta4 receptor agonist | 0.034 0.015 DBMET03353 | DBMET03353 | |
| 0.005 | 0.058 | 0.011 | Egl nine homolog 3 inhibitor | 0.011 0.009 DBMET03353 | DBMET03353 | |
| 0.025 | 0.083 | 0.051 | Geranyltranstransferase inhibitor | 0.051 0.022 DBMET03353 | DBMET03353 | |
| 0.064 | 0.122 | 0.093 | NADH dehydrogenase inhibitor | 0.093 0.052 DBMET03353 | DBMET03353 | |
| 0.042 | 0.1 | 0.121 | Histidine decarboxylase inhibitor | 0.121 0.025 DBMET03353 | DBMET03353 | |
| 0.097 | 0.156 | 0.15 | Mannose-6-phosphate isomerase inhibitor | 0.15 0.065 DBMET03353 | DBMET03353 | |
| 0.066 | 0.127 | 0.098 | D-Ala-D-Ala ligase inhibitor | 0.098 0.031 DBMET03353 | DBMET03353 | |
| 0.055 | 0.117 | 0.102 | Opioid kappa receptor antagonist | 0.102 0.033 DBMET03353 | DBMET03353 | |
| 0.044 | 0.107 | 0.056 | Immunoglobulin Fc receptor antagonist | 0.056 0.036 DBMET03353 | DBMET03353 | |
| 0.147 | 0.211 | 0.176 | DNA synthesis inhibitor | 0.176 0.16 DBMET03353 | DBMET03353 | |
| 0.115 | 0.181 | 0.379 | Aldehyde oxidase inhibitor | 0.379 0.05 DBMET03353 | DBMET03353 | |
| 0.017 | 0.085 | 0.061 | Estrogen agonist | 0.061 0.029 DBMET03353 | DBMET03353 | |
| 0.09 | 0.162 | 0.116 | Cell wall synthesis inhibitor | 0.116 0.106 DBMET03353 | DBMET03353 | |
| 0.038 | 0.112 | 0.067 | Purinergic P2X1 antagonist | 0.067 0.034 DBMET03353 | DBMET03353 | |
| 0.016 | 0.09 | 0.027 | Purinergic P2Y15 antagonist | 0.027 0.024 DBMET03353 | DBMET03353 | |
| 0.12 | 0.196 | 0.161 | Neurotensin receptor agonist | 0.161 0.077 DBMET03353 | DBMET03353 | |
| 0.024 | 0.099 | 0.058 | Xanthine dehydrogenase inhibitor | 0.058 0.039 DBMET03353 | DBMET03353 | |
| 0.063 | 0.142 | 0.109 | Lanosterol 14 alpha demethylase inhibitor | 0.109 0.044 DBMET03353 | DBMET03353 | |
| 0.007 | 0.086 | 0.021 | Nicotinic acid receptor 1 antagonist | 0.021 0.008 DBMET03353 | DBMET03353 | |
| 0.156 | 0.239 | 0.261 | Insulysin inhibitor | 0.261 0.087 DBMET03353 | DBMET03353 | |
| 0.017 | 0.1 | 0.028 | Estrogen-related receptor gamma antagonist | 0.028 0.021 DBMET03353 | DBMET03353 | |
| 0.039 | 0.133 | 0.064 | Aryl hydrocarbon receptor antagonist | 0.064 0.047 DBMET03353 | DBMET03353 | |
| 0.06 | 0.155 | 0.126 | Carbonic anhydrase III inhibitor | 0.126 0.04 DBMET03353 | DBMET03353 | |
| 0.016 | 0.113 | 0.051 | Alpha 1d adrenoreceptor agonist | 0.051 0.016 DBMET03353 | DBMET03353 | |
| 0.066 | 0.165 | 0.107 | Interleukin 12 antagonist | 0.107 0.044 DBMET03353 | DBMET03353 | |
| 0.052 | 0.157 | 0.078 | Estrogen receptor alpha antagonist | 0.078 0.051 DBMET03353 | DBMET03353 | |
| 0.007 | 0.115 | 0.02 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.02 0.018 DBMET03353 | DBMET03353 | |
| 0.045 | 0.158 | 0.072 | Carbonic anhydrase VI inhibitor | 0.072 0.069 DBMET03353 | DBMET03353 | |
| 0.051 | 0.17 | 0.077 | GABA B receptor agonist | 0.077 0.048 DBMET03353 | DBMET03353 | |
| 0.087 | 0.207 | 0.146 | Heat shock protein 90 alpha antagonist | 0.146 0.091 DBMET03353 | DBMET03353 | |
| 0.15 | 0.278 | 0.232 | Toll-Like receptor 7 agonist | 0.232 0.165 DBMET03353 | DBMET03353 | |
| 0.067 | 0.197 | 0.141 | Estrogen antagonist | 0.141 0.027 DBMET03353 | DBMET03353 | |
| 0.147 | 0.283 | 0.225 | Toll-Like receptor agonist | 0.225 0.174 DBMET03353 | DBMET03353 | |
| 0.058 | 0.197 | 0.102 | Carbonic anhydrase XV inhibitor | 0.102 0.064 DBMET03353 | DBMET03353 | |
| 0.078 | 0.221 | 0.127 | Heat shock protein 90 antagonist | 0.127 0.102 DBMET03353 | DBMET03353 | |
| 0.082 | 0.225 | 0.173 | NOS3 expression enhancer | 0.173 0.054 DBMET03353 | DBMET03353 | |
| 0.004 | 0.151 | 0.059 | Estrogen receptor alpha agonist | 0.059 0.015 DBMET03353 | DBMET03353 | |
| 0.047 | 0.204 | 0.139 | 5 Hydroxytryptamine 3A agonist | 0.139 0.042 DBMET03353 | DBMET03353 | |
| 0.052 | 0.21 | 0.111 | Nav1.6 sodium channel blocker | 0.111 0.11 DBMET03353 | DBMET03353 | |
| 0.028 | 0.2 | 0.063 | 5 Hydroxytryptamine 3 agonist | 0.063 0.044 DBMET03353 | DBMET03353 | |
| 0.024 | 0.196 | 0.07 | Protein kinase C beta inhibitor | 0.07 0.048 DBMET03353 | DBMET03353 | |
| 0.021 | 0.197 | 0.065 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.065 0.025 DBMET03353 | DBMET03353 | |
| 0.036 | 0.212 | 0.087 | Opioid antagonist | 0.087 0.06 DBMET03353 | DBMET03353 | |
| 0.071 | 0.255 | 0.127 | Hexokinase inhibitor | 0.127 0.108 DBMET03353 | DBMET03353 | |
| 0.159 | 0.364 | 0.352 | Calcium channel L-type activator | 0.352 0.116 DBMET03353 | DBMET03353 | |
| 0.023 | 0.235 | 0.039 | CF transmembrane conductance regulator antagonist | 0.039 0.032 DBMET03353 | DBMET03353 | |
| 0.004 | 0.234 | 0.037 | Estrogen receptor beta agonist | 0.037 0.022 DBMET03353 | DBMET03353 | |
| 0.096 | 0.335 | 0.147 | Cyclin-dependent kinase 3 inhibitor | 0.147 0.104 DBMET03353 | DBMET03353 | |
| 0.08 | 0.327 | 0.186 | 5 Hydroxytryptamine 1E antagonist | 0.186 0.146 DBMET03353 | DBMET03353 | |
| 0.038 | 0.287 | 0.132 | Estrogen receptor beta antagonist | 0.132 0.022 DBMET03353 | DBMET03353 | |
| 0.04 | 0.295 | 0.087 | MAP kinase kinase 7 inhibitor | 0.087 0.03 DBMET03353 | DBMET03353 | |
| 0.051 | 0.316 | 0.085 | CC chemokine 5 receptor agonist | 0.085 0.048 DBMET03353 | DBMET03353 | |
| 0.005 | 0.339 | 0.033 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.033 0.026 DBMET03353 | DBMET03353 | |
| 0.067 | 0.459 | 0.142 | MAP kinase kinase 4 inhibitor | 0.142 0.08 DBMET03353 | DBMET03353 | |
| 0.01 | 0.419 | 0.035 | Estrogen-related receptor beta antagonist | 0.035 0.017 DBMET03353 | DBMET03353 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |